Verified predominance of slow acetylator phenotype N-acetyltransferase 2 (NAT2) in a Hmong population residing in Minnesota

Biopharmaceutics and Drug Disposition

Volumn 27, Issue 6, 2006, Pages 299-304

  Straka, Robert J ^a   Burkhardt, R Todd ^a   Lang, Nicholas P ^b   Vang, Ter ^a   Hadsall, Kelly Z ^c   Tsai, Michael Y ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^c NORTH MEMORIAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Hmong; Metabolism; N acetyltransferase 2; NAT2; Phenotype

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CAFFEINE;

ACETYLATOR PHENOTYPE; ADULT; AGED; ARTICLE; ASIAN; CHI SQUARE TEST; ENZYME ASSAY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEREDITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POPULATION GENETICS; POPULATION RESEARCH; PREVALENCE; UNITED STATES; URINALYSIS; URINE LEVEL;

ACETYLATION; ADOLESCENT; ADULT; AGED; ARYLAMINE N-ACETYLTRANSFERASE; FEMALE; GENE FREQUENCY; HUMANS; KINETICS; MALE; MIDDLE AGED; MINNESOTA; PHARMACEUTICAL PREPARATIONS; PHENOTYPE; UNITED STATES; VIETNAM;

EID: 33749355571     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.506     Document Type: Article

References (30)

1. Le Marchand L, Hankin JH, Wilkens LR, et al. Combined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10: 1259-1266.
2. Cartwright RA, Glashan RW, Rogers HJ, et al. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982; 2: 842-845.
3. Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-889. DOI:10.1053/jhep.2002.32102
4. Hussain Z, Kar P, Husain SA. Antituberculosis drug-induced hepatitis: risk factors, prevention and management. Indian J Exp Biol 2003; 41: 1226-1232.
5. Dickinson DS, Bailey WC, Hirschowitz BI, Soong SJ, Eidus L, Hodgkin MM. Risk factors for isoniazid (NIH)-induced liver dysfunction. J Clin Gastroenterol 1981; 3: 271-279.
6. Mitchell JR, Thorgeirsson UP, Black M, et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 1975; 18: 70-79.
7. Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 1976; 84: 181-192.
8. Yew WW. Risk factors for hepatotoxicity during antituberculosis chemotherapy in Asian populations. Int J Tuberc Lung Dis 2001; 5: 99-100.
9. Evans DA. N-acetyltransferase. Pharmacol Ther 1989; 42: 157-234.
10. Horai Y, Zhou HH, Zhang LM, Ishizaki T. N-acetylation phenotyping with dapsone in a mainland Chinese population. Br J Clin Pharmacol 1988; 25: 81-87.
11. Kukongviriyapan V, Lulitanond V, Areejitranusorn C, Kongyingyose B, Laupattarakasem P. N-acetyltransferase polymorphism in Thailand. Hum Hered 1984; 34: 246-249.
12. Straka RJ, Hansen SR, Benson SR, Walker PF. Predominance of slow acetylators of N-acetyltransferase in a Hmong population residing in the United States. J Clin Pharmacol 1996; 36: 740-747.
13. Minnesota Department of Health. http://www.health. state.mn.us/divs/ idepc/diseases/tb/fbtbslides.html [February 17, 2005].
14. Mills PK, Yang R. Cancer incidence in the Hmong of Central California, United States, 1987-94. Cancer Causes Control 1997; 8: 705-712.
15. Ross JA, Xie Y, Kiffmeyer WR, Bushhouse S, Robison LL. Cancer in the Minnesota Hmong population. Cancer 2003; 97: 3076-3079. DOI:10.1002/ cncr.11443
16. Butler MA, Lang NP, Young JF, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116-127.
17. Rosner B. Fundamentals of Biostatistics. Duxbury Press: Pacific Grove, CA, 2000; xix, 792 pp.
18. United States. Bureau of the Census. 2000 Census of Population and Housing. Summary Population and Housing Characteristics. [name of state]. U.S. Department of Commerce, Economics and Statistics Administration. For sale by the Supt. of Docs., U.S. G.P.O.: Washington, DC, 2002; 53 v. in 56 pp.
19. MMWR Weekly. Multidrug-Resistant Tuberculosis in Hmong Refugees Resettling from Thailand in to the United States, 2004-2005, Table. Tuberculosis (TB) disease in Hmong refugees resettled from Thailand into the United States, by state - June 2004-January 2005; published August 5,2005; . CDC: U.S. Department of Health and Human Services.
20. Trends in tuberculosis - United States, 2004. MMWR Morb Mortal Wkly Rep 2005; 54: 245-249. DOI:mm5410a2 [pii]
21. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 2004; 279: 23847-23850. DOI:10.1074/ jbc.R400004200
22. Nebert DW, McKinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 1996; 15: 273-280.
23. Kalow W, Tang BK. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1991; 49: 44-48.
24. Grant DM, Tang BK, Kalow W. Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther 1983; 33: 355-359.
25. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1984; 17: 459-464.
26. Nyeki A, Buclin T, Biollaz J, Decosterd LA. NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios. Br J Clin Pharmacol 2003; 55: 62-67.
27. Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther 1991; 49: 648-657.
28. Le Marchand L, Sivaraman L, Franke AA, et al. Predictors of N-acetyltransferase activity: should caffeine phenotyping and NAT2 genotyping be used interchangeably in epidemiological studies? Cancer Epidemiol Biomarkers Prev 1996; 5: 449-455.
29. Bell DA, Stephens EA, Castranio T, et al. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 1995; 55: 3537-3542.
30. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995; 57: 581-592.